BGMS: רווח נקי למניה ב-12 החודשים האחרונים cyclacel.com
The current EPS TTM level clearly demonstrates the financial results of Bio Green Med Solution Inc, while -2.37 captures the magnitude of this parameter. The developer faces a dependence on external funding and a lack of sales. However, ownership of patents for cell cycle regulation creates a valuation base. Currently, the startup is scaling its kinase inhibitor portfolio through a strategic alliance with pharma behemoths.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_BGMS_-_Bio-Green-Med-Solution-Inc_-_Earnings-per-share-for-the-last-four-quarters "Cyclacel Pharmaceuticals - רווח נקי למניה (EPS TTM) BGMS (תקופה 13.09.2025 - 14.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Bio Green Med Solution Inc
The business stability of Bio Green Med Solution Inc. (BGMS) depends on the successful implementation of automation in oncology diagnostics. This indicator reflects the proportional income, calculated as the ratio of net profit to the total number of shares for the year. By analyzing the 12-month net income per share trend, an investor tracks the actual efficiency of capitalization. Growth in this metric confirms the scaling of software robots, which allows for an objective determination of the issuer's fair value.
